Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
10.00 EUR
1.05 B EUR
8.53 B EUR
144.68 M
About Biogen Inc.
Sector
CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
FIGI
BBG01K3X4XJ1
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
$BIIB imploding to the downsideStock is leaking out lows, next stop 182.23 where we should bounce. Until then i am #bearish
BIIB Long, Coming Soon!The price has sold off from the $207.59 pivot level, dropping to $193.84 as of the Monday, September 30th close. The sharp decline from $200 to $190 over two days last week was largely due to sector-wide weakness, as reflected in the IBB (Biotech ETF). Since then, both the ETF and BIIB have been con
BIIB - Breakout soonBIIB is forming a tight pennant setup. Either this gonna breakout here and rally or Fakeout and crash. Let’s see..!
Long anywhere here.
Target #1 - 250
Target #2 - 260
Target #3 - 275
Stop loss - 225
BIIB bear trend breakout? BIIB has broken a long running bearish trend since Jan 2023
Entry @ 223
TP1 @ 255
SL @ 200
Fundamentally strong stock hence the far off Stop loss but still a 1:2 ratio risk reward
Biogen Stock Surge 4.85% on Approval For ALS DrugBiogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical need
Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 cu
9 year consolidation about over?Might make this one a core position over the coming months... 200 month moving average tested successfully once already.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 1BIIB is featured.
Frequently Asked Questions
The current price of 1BIIB is 152.45 EUR — it has increased by 1.77% in the past 24 hours. Watch BIOGEN stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BIOGEN stocks are traded under the ticker 1BIIB.
1BIIB stock has fallen by −3.97% compared to the previous week, the month change is a −10.24% fall, over the last year BIOGEN has showed a −26.49% decrease.
We've gathered analysts' opinions on BIOGEN future price: according to them, 1BIIB price has a max estimate of 322.85 EUR and a min estimate of 169.92 EUR. Watch 1BIIB chart and read a more detailed BIOGEN stock forecast: see what analysts think of BIOGEN and suggest that you do with its stocks.
1BIIB reached its all-time high on Jan 9, 2024 with the price of 244.60 EUR, and its all-time low was 146.70 EUR and was reached on Nov 20, 2024. View more price dynamics on 1BIIB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1BIIB stock is 1.74% volatile and has beta coefficient of 0.76. Track BIOGEN stock price on the chart and check out the list of the most volatile stocks — is BIOGEN there?
Today BIOGEN has the market capitalization of 21.97 B, it has decreased by −0.62% over the last week.
Yes, you can track BIOGEN financials in yearly and quarterly reports right on TradingView.
BIOGEN is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
1BIIB earnings for the last quarter are 3.66 EUR per share, whereas the estimation was 3.39 EUR resulting in a 8.15% surprise. The estimated earnings for the next quarter are 3.27 EUR per share. See more details about BIOGEN earnings.
BIOGEN revenue for the last quarter amounts to 2.21 B EUR, despite the estimated figure of 2.19 B EUR. In the next quarter, revenue is expected to reach 2.31 B EUR.
1BIIB net income for the last quarter is 348.93 M EUR, while the quarter before that showed 544.85 M EUR of net income which accounts for −35.96% change. Track more BIOGEN financial stats to get the full picture.
No, 1BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 7.57 K employees. See our rating of the largest employees — is BIOGEN on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN EBITDA is 2.47 B EUR, and current EBITDA margin is 22.58%. See more stats in BIOGEN financial statements.
Like other stocks, 1BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN stock shows the strong sell signal. See more of BIOGEN technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.